Full Text
The Economic Impact of Switching To Herceptin (TRASTUZUMAB) Biosimilar for The Treatment of Metastatic Breast Cancer From A UK Payer Perspective

Abstract

Authors

D Brown D Bozkaya LLC Xcenda

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×